Mersana Therapeutics (MRSN) has disclosed a new risk, in the Capital Markets category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mersana Therapeutics faces significant business risks due to the uncertainty surrounding U.S. trade policy, particularly the tariffs imposed by the Trump Administration. The 10% baseline reciprocal tariff on all U.S. trading partners, along with higher tariffs on China, Canada, and Mexico, could adversely affect the company’s supply chain and increase production costs. Additionally, the ongoing Section 232 investigation into pharmaceutical imports may lead to further tariffs, exacerbating potential disruptions. These factors could delay the development and approval of Mersana’s product candidates, posing a material threat to its financial condition and operational results.
Overall, Wall Street has a Strong Buy consensus rating on MRSN stock based on 6 Buys and 1 Hold.
To learn more about Mersana Therapeutics’ risk factors, click here.